Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InflaRx N.V. (IFRX : NSDQ)

• Company Description    InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $1.50 Daily Weekly Monthly 20 Day Moving Average: 120,439 shares Shares Outstanding: 44.20 (millions) Market Capitalization: $66.31 (millions) Beta: 0.82 52 Week High: $5.69 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.73% -5.08% 12 Week -51.77% -46.97% Year To Date -68.49% -61.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL WINZERLAER STR. 2 - JENA,2M 07745 DEU ph: 49-36-4150-8180 fax: - jordan.zwick@inflarx.de http://www.inflarx.de

• General Corporate Information    Officers Niels Riedemann - Executive Director and Chief Executive Officer Nicolas Fulpius - Chairman Thomas Taapken - Chief Financial Officer Richard Brudnick - Director Mark Kubler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N44821101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 44.20 Most Recent Split Date: (:1) Beta: 0.82 Market Capitalization: $66.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.62 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -63.64% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -48.22 12/31/21 - -37.38 09/30/21 - -36.94 ROA 03/31/22 - -42.01 12/31/21 - -33.64 09/30/21 - -33.68 Current Ratio 03/31/22 - 5.47 12/31/21 - 5.10 09/30/21 - 7.74 Quick Ratio 03/31/22 - 5.47 12/31/21 - 5.10 09/30/21 - 7.74 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 2.41 12/31/21 - 2.82 09/30/21 - 3.14 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©